Related Experiment Videos
[Fundamental and clinical studies on tazobactam/piperacillin in the pediatric field]
K Kitamura1, H Nishimori, T Ihara
1Department of Pediatrics, Mie National Hospital.
Insights
Tazobactam/piperacillin demonstrated 100% efficacy in pediatric infections, with favorable pharmacokinetics and a good safety profile. This combination antibiotic is a promising option for treating various pediatric bacterial infections.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Antimicrobial therapy
Background:
- Beta-lactamase inhibitors combined with penicillin antibiotics offer a strategy against resistant bacteria.
- Piperacillin/tazobactam (TAZ/PIPC) is a combination antibiotic with potential utility in pediatric populations.
Purpose of the Study:
- To evaluate the pharmacokinetics, efficacy, and safety of tazobactam/piperacillin in pediatric patients.
- To assess the clinical and bacteriological outcomes of TAZ/PIPC treatment in children.
Main Methods:
- Pharmacokinetic analysis of serum concentration and urinary excretion of TAZ/PIPC in one pediatric patient.
- Clinical efficacy and safety assessment in 10 pediatric patients with various infections (respiratory, pharyngotonsillitis, pertussis, skin).
Main Results:
- Serum half-lives were 0.5 hours for tazobactam and 0.6 hours for piperacillin.
- 100% clinical efficacy observed (5 excellent, 5 good responses).
- Bacteriological eradication in 2 cases; mild adverse events (rash, transient lab abnormalities) reported.
Conclusions:
- Tazobactam/piperacillin exhibits favorable pharmacokinetic properties in children.
- TAZ/PIPC demonstrated high efficacy and a favorable safety profile in treating pediatric infections.
- The study suggests TAZ/PIPC is a useful antibiotic option for pediatric use.
Abstract:
Pharmacokinetics, efficacy and safety of tazobactam/piperacillin (TAZ/PIPC), a new beta-lactamase inhibitor combined with a penicillin antibiotic, were studied in pediatrics and the following results were obtained. 1) Serum concentration and urinary excretion of TAZ/PIPC after intravenous administration at a dose of 46 mg/kg to one child were investigated. Serum half-lives were 0.5 hours for TAZ and 0.6 hours for PIPC, while the urinary recovery rates in the first 6 hours after administration, were 61.6% and 56.3% respectively. 2) TAZ/PIPC was administered at a dose of 46.0-73.5 mg/kg t.i.d. for 3-13 days to 10 patients, 6 with respiratory infection, 1 with pharyngotonsillitis, 1 with pertussis and 2 with soft tissue infection of skin. Clinical response were excellent in 5 cases and good in 5 cases, and the efficacy rate was 100%. Bacteriologically, 2 strains (Staphylococcus aureus and Streptococcus pyogenes) isolated from 2 patients were eradicated after the treatment. As for adverse reaction, mild skin rash was observed in 1 case but disappeared within 2 days after withdrawal of the drug. As for abnormal laboratory test results decrease in neutrophiles and increase in eosinophiles in each 1 case were observed, which were, however, normalized after administration. From the above results, tazobactam/piperacillin was considered to be a useful antibiotic in the pediatric field.